Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 4/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82119 | 1.00 | PTAFR (0.33) | PTAFRCYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL29475074 | 1.00 | PTAFR (0.33) | PTAFRCYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL82120 | 1.00 | PTAFR (0.33) | PTAFRCYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL87081 | 0.93 | KDM4E (0.32) | PTAFRCYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL86783 | 0.92 | CHRNB2 (0.36) | PTAFRKDM4EALDH1A1CYP1A1CYP1A2 | |
| SCHEMBL86675 | 0.92 | KMT2A (0.33) | PTAFRKDM4EALDH1A1CYP1A1CYP1A2 | |
| SCHEMBL82254 | 0.91 | KDM4E (0.32) | PTAFRKDM4EALDH1A1CYP1A1CYP1A2 | |
| SCHEMBL86380 | 0.91 | KDM4E (0.32) | PTAFRKDM4EALDH1A1CYP1A1CYP1A2 | |
| SCHEMBL82253 | 0.91 | KDM4E (0.32) | PTAFRKDM4EALDH1A1CYP1A1CYP1A2 | |
| SCHEMBL82158 | 0.90 | CYP1A1 (0.39) | PTAFRKDM4EALDH1A1CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| EP-2042504-B1 | Fused azole-pyrimidine derivatives | BAYER SCHERING PHARMA AG (DE) | 2011-06-01 | — | — | EP | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | PTAFR 119/4885CYP11B1 500/4885CYP11B2 637/4885 |
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | KIT, CSNK2A1, CSNK1A1 | PTAFR 1757/4885CYP11B1 1935/4885CYP11B2 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.